Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

INTRODUCTION: Heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) have limited viable antiretroviral regimens available because of multidrug resistance and safety concerns. The first-in-class HIV-1 attachment inhibitor fostemsavir demonstrated efficacy and safety in HTE participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Sarah-Jane, Murray, Miranda, Cella, David, Grossberg, Robert, Hagins, Debbie, Towner, William, Wang, Marcia, Clark, Andrew, Pierce, Amy, Llamoso, Cyril, Ackerman, Peter, Lataillade, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739158/
https://www.ncbi.nlm.nih.gov/pubmed/34180035
http://dx.doi.org/10.1007/s40271-021-00534-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739158/
https://www.ncbi.nlm.nih.gov/pubmed/34180035
http://dx.doi.org/10.1007/s40271-021-00534-y

Ejemplares similares